Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 539,600 shares, a decrease of 26.7% from the February 13th total of 736,300 shares. Approximately 4.4% of the shares of the company are sold short. Based on an average daily trading volume, of 1,420,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Two Sigma Securities LLC bought a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.15% of Cyclo Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 68.55% of the company’s stock.

Cyclo Therapeutics Stock Down 1.7 %

CYTH traded down $0.01 on Tuesday, hitting $0.65. 64,925 shares of the company traded hands, compared to its average volume of 408,680. The company has a 50 day moving average of $0.79 and a 200-day moving average of $0.73. The stock has a market capitalization of $21.40 million, a PE ratio of -0.72 and a beta of -0.57. Cyclo Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.79.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.